FDA Approves Elevidys (delandistrogene moxeparvovec-rokl) Gene Therapy to Treat DuchenneMuscular Dystrophy
June 22, 2023
FDA Approves Litfulo (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
June 23, 2023June 22, 2023 - Sebela Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval of Suflave TM(polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults. Suflave, a low-volume, safe and effective colonoscopy preparation – with a taste similar to a lemon-lime sports drink – was developed and will be marketed by Braintree Laboratories, part of Sebela Pharmaceuticals.
Additionally, colonoscopy preparation products and processes are commonly cited as a significant patient barrier to colon cancer screening, reinforcing an unmet need among patients for better bowel preparation options. Tolerance of bowel preparation remains the largest deterrent for patients considering screening colonoscopy with 71% of patients saying it is the worst part of colonoscopy and 55% indicating it was the greatest deterrent to a future colonoscopy. Prep volume, palatability and patient education are three key factors in reducing prep hesitancy.
Suflave will be available by prescription to patients in the U.S. in early August.